Melatonin in chagas disease. Possible therapeutic valuela;La Melatonina en la enfermedad de chagas. Su posible valor terapéutico

Medicina

Volumn 71, Issue 5, 2011, Pages 477-483

  Cardinali, Daniel P ^a   Alvarez, Carlos B ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA ARGENTINA   (Argentina)

Author keywords

Chagas; Disease; Melatonin; Melatonin receptors; Nitric oxide; Oxidative stress

Indexed keywords

MELATONIN; NITRIC OXIDE; RAMELTEON; REACTIVE OXYGEN METABOLITE;

ADAPTIVE IMMUNITY; ANTIOXIDANT ACTIVITY; ARTICLE; CHAGAS DISEASE; DISEASE COURSE; HEART MUSCLE INJURY; HUMAN; INNATE IMMUNITY; NONHUMAN; OXIDATIVE STRESS; TH1 CELL; TRYPANOSOMA CRUZI;

ANIMALS; ANTIOXIDANTS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CHAGAS CARDIOMYOPATHY; CHAGAS DISEASE; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFLAMMATION MEDIATORS; MELATONIN; NITRIC OXIDE; OXIDATIVE STRESS; PARASITEMIA; RECEPTORS, MELATONIN; TRYPANOSOMA CRUZI;

EID: 84857573856     PISSN: 00257680     EISSN: 16699106     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Paredes SD, Korkmaz A, Manchester LC, Tan DX, Reiter RJ. Phytomelatonin: a review. J Exp Bot 2009; 60: 57-69.
2. Macias M, Rodriguez-Cabezas MN, Reiter RJ, Osuna A, Acuna-Castroviejo D. Presence and effects of melatonin in Trypanosoma cruzi. J Pineal Res 1999; 27: 86-94.
3. Hardeland R, Cardinali DP, Srinivasan V, Spence DW, Brown GM, Pandi-Perumal SR. Melatonin. A pleiotropic, orchestrating regulator molecule. Progr Neurobiol 2011; 93: 350-84.
4. Srinivasan V, Pandi-Perumal SR, Spence DW, Kato H, Cardinali DP. Melatonin in septic shock: Some recent concepts. J Crit Care 2010; 25: 656.e1-656.e6.
5. Coura JR, Dias JC. Epidemiology, control and surveillance of Chagas disease: 100 years after its discovery. Mem Inst Oswaldo Cruz 2009; 104 (Suppl 1): 31-40.
6. Bar ME, Oscherov EB, Pieri DM, Borda M. Epidemiología de la tripanosomiasis americana en el Norte de Corrientes. Medicina (B Aires) 2010; 70: 133-8.
7. de Rissio AM, Scollo K, Cardoni RL. Transmisión materno-fetal del Trypanosoma cruzi en Argentina. Medicina (B Aires) 2009; 69: 529-35.
8. Sathler-Avelar R, Vitelli-Avelar DM, Teixeira-Carvalho A, Martins-Filho OA. Innate immunity and regulatory T-cells in human Chagas disease: what must be understood? Mem Inst Oswaldo Cruz 2009; 104 (Suppl 1): 246-51.
9. Cunha-Neto E, Nogueira LG, Teixeira PC, et al. Immunological and non-immunological effects of cytokines and chemokines in the pathogenesis of chronic Chagas disease cardiomyopathy. Mem Inst Oswaldo Cruz 2009; 104 (Suppl 1): 252-8.
10. Gonzalez-Cappa S. Inmunopatología en enfermedad de Chagas experimental. Medicina (B Aires) 2000; 60: 681-4.
11. Roldan EJ. Tratamiento de la enfermedad de Chagas con benznidazol y ácido tióctico. Medicina (B Aires) 2005; 65: 85-6.
12. Sosa-Estani S, Armenti A, Araujo G, et al. Tratamiento de la enfermedad de Chagas con benznidazol y ácido tióctico. Medicina (B Aires) 2004; 64: 1-6.
13. Santello FH, Frare EO, Dos Santos CD, et al. Melatonin treatment reduces the severity of experimental Trypanosoma cruzi infection. J Pineal Res 2007; 42: 359-63.
14. Santello FH, Frare EO, Caetano LC, AlonsoToldo MP, do Prado JC Jr. Melatonin enhances pro-inflammatory cytokine levels and protects against Chagas disease. J Pineal Res 2008; 45: 79-85.
15. Santello FH, Frare EO, Dos Santos CD, Caetano LC, Alonso Toldo MP, do Prado JC Jr. Suppressive action of melatonin on the TH-2 immune response in rats infected with Trypanosoma cruzi. J Pineal Res 2008; 45: 291-6.
16. Zhang S, Li W, Gao Q, Wei T. Effect of melatonin on the generation of nitric oxide in murine macrophages. Eur J Pharmacol 2004; 501: 25-30.
17. Gupta S, Wen JJ, Garg NJ. Oxidative stress in Chagas disease. Interdiscip Perspect Infect Dis 2009; 2009: 190354.
18. Lardone PJ, Carrillo-Vico A, Molinero P, Rubio A, Guerrero JM. A novel interplay between membrane and nuclear melatonin receptors in human lymphocytes: significance in IL-2 production. Cell Mol Life Sci 2009; 66: 516-25.
19. Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev 2010; 62: 343-80.
20. Guerrero JM, Pozo D, Garcia-Maurino S, Osuna C, Molinero P, Calvo JR. Involvement of nuclear receptors in the enhanced IL-2 production by melatonin in Jurkat cells. Ann N Y Acad Sci 2000; 917: 397-403.
21. Maldonado MD, Mora-Santos M, Naji L, Carrascosa-Salmoral MP, Naranjo MC, Calvo JR. Evidence of melatonin synthesis and release by mast cells. Possible modulatory role on inflammation. Pharmacol Res 2010; 62: 282-87.
22. Cardinali DP, Ritta MN. The role of prostaglandins in neuroendocrine junctions: studies in the pineal gland and the hypothalamus. Neuroendocrinology 1983; 36: 152-60.
23. Deng WG, Tang ST, Tseng HP, Wu KK. Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood 2006; 108: 518-24.
24. Reiter RJ, Paredes SD, Manchester LC, Tan DX. Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol 2009; 44: 175-200.
25. Acuña Castroviejo D, Lopez LC, Escames G, Lopez A, Garcia JA, Reiter RJ. Melatonin-mitochondria Interplay in Health and Disease. Curr Top Med Chem 2011;11:221-40.
26. Tan DX, Poeggeler B, Reiter RJ, et al. The pineal hormone melatonin inhibits DNA-adduct formation induced by the chemical carcinogen safrole in vivo. Cancer Lett 1993; 70: 65-71.
27. Tan D, Reiter RJ, Chen LD, Poeggeler B, Manchester LC, Barlow-Walden LR. Both physiological and pharmacological levels of melatonin reduce DNA adduct formation induced by the carcinogen safrole. Carcinogenesis 1994; 15: 215-8.
28. Acuña-Castroviejo D, Escames G, Rodriguez MI, Lopez LC. Melatonin role in the mitochondrial function. Front Biosci 2007; 12: 947-63.
29. Mathes A, Kubuls D, Waibel L, et al. Selective activation of melatonin receptors with ramelteon improves liver function and hepatic perfusion after hemorrhagic shock in rat. Crit Care Med 2008; 36: 2863-70.
30. Tanowitz HB, Machado FS, Jelicks LA, et al. Perspectives on Trypanosoma cruzi-induced heart disease (Chagas disease). Prog Cardiovasc Dis 2009; 51: 524-39.
31. Sosa ES, Segura EL. Tratamiento de la infección por Trypanosoma cruzi en fase indeterminada. Experiencia y normatización actual en la Argentina. Medicina (B Aires) 1999; 59 (Suppl 2): 166-70.
32. Elizari MV. Miocardiopatía chagásica: perspective histórica. Medicina (B Aires) 1999; 59 Suppl 2: 25-40.
33. Rigou DG, Gullone N, Carnevali L, De Rosa AF. Enfermedad de Chagas asintomática. Hallazgos electrocardiográficos y ecocardiográficos. Medicina (B Aires) 2001; 61: 541-4.
34. Cunha-Neto E. Repensando la patogenia de la cardiopatía crónica chagásica en el fin del milenio. Medicina (B Aires) 1999; 59: 496-500.
35. Noireau F, Diosque P, Jansen AM. Trypanosoma cruzi: adaptation to its vectors and its hosts. Vet Res 2009; 40: 26.
36. Oliveira LG, Kuehn CC, Santos CD, Toldo MP, do PJ, Jr. Enhanced protection by melatonin and meloxicam combination in experimental infection by Trypanosoma cruzi. Parasite Immunol 2010; 32: 245-51.
37. Ribeiro CM, Budni P, Pedrosa RC, et al. Antioxidant therapy attenuates oxidative insult caused by benzonidazole in chronic Chagas' heart disease. Int J Cardiol 2010; 145:27-33.
38. Kittleson MM, Lowenstein CJ, Hare JM. Novel pathogenetic mechanisms in myocarditis: nitric oxide signaling. Heart Fail Clin 2005; 1: 345-61.
39. de Oliveira TB, Pedrosa RC, Filho DW. Oxidative stress in chronic cardiopathy associated with Chagas disease. Int J Cardiol 2007; 116: 357-63.
40. Wen JJ, Vyatkina G, Garg N. Oxidative damage during chagasic cardiomyopathy development: role of mitochondrial oxidant release and inefficient antioxidant defense. Free Radic Biol Med 2004; 37: 1821-33.
41. Reiter RJ, Tan DX, Paredes SD, Fuentes-Broto L. Beneficial effects of melatonin in cardiovascular disease. Ann Med 2010; 42: 276-85.
42. Reiter RJ, Manchester LC, Fuentes-Broto L, Tan DX. Cardiac hypertrophy and remodelling: pathophysiological consequences and protective effects of melatonin. J Hypertens 2010; 28 Suppl 1: S7-S12.
43. Tan DX, Manchester LC, Reiter RJ, Qi W, Kim SJ, El Sokkary GH. Ischemia/reperfusion-induced arrhythmias in the isolated rat heart: prevention by melatonin. J Pineal Res 1998; 25: 184-91.
44. Kaneko S, Okumura K, Numaguchi Y, et al. Melatonin scavenges hydroxyl radical and protects isolated rat hearts from ischemic reperfusion injury. Life Sci 2000; 67: 101-12.
45. Salie R, Harper I, Cillie C, et al. Melatonin protects against ischaemic-reperfusion myocardial damage. J Mol Cell Cardiol 2001; 33: 343-57.
46. Sahna E, Parlakpinar H, Turkoz Y, Acet A. Protective effects of melatonin on myocardial ischemia/reperfusion induced infarct size and oxidative changes. Physiol Res 2005; 54: 491-5.
47. Castagnino HE, Lago N, Centrella JM, et al. Cytoprotection by melatonin and growth hormone in early rat myocardial infarction as revealed by Feulgen DNA staining. Neuro Endocrinol Lett 2002; 23: 391-5.
48. Srinivasan V, Spence DW, Moscovitch A, et al. Malaria: therapeutic implications of melatonin. J Pineal Res 2010; 48: 1-8.
49. Jahnke G, Marr M, Myers C, Wilson R, Travlos G, Price C. Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats. Toxicol Sci 1999; 50: 271-9.
50. Voordouw BC, Euser R, Verdonk RE, et al. Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. J Clin Endocrinol Metab 1992; 74: 108-17.
51. Molina-Carballo A, Munoz-Hoyos A, Reiter RJ, et al. Utility of high doses of melatonin as adjunctive anticonvulsant therapy in a child with severe myoclonic epilepsy: two years' experience. J Pineal Res 1997; 23: 97-105.
52. Jan JE, Wasdell MB, Freeman RD, Bax M. Evidence supporting the use of melatonin in short gestation infants. J Pineal Res 2007; 42: 22-7.
53. Seabra ML, Bignotto M, Pinto LR, Jr, Tufik S. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J Pineal Res 2000; 29: 193-200.